DDX6 reshapes the cancer RNA editome to suppress RNA-induced innate immunity
RNA-seq (gene expression) · human · 57 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 57 samples: 50 distinct titles, 7 of them repeatedGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE234654_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA982700 and SRA study SRP442843. Searching any of these in the dataset finder brings you back here.
How we read this: Read from 57 sample titles: 50 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7472847 shScr (DDX6)
- GSM7472848 shDDX6 #6
- GSM7472849 shDDX6 #9
- GSM7472850 shScr (DDX3X)
- GSM7472851 shDDX3X #1
- GSM7472852 shDDX3X #2
- GSM7472853 shScr (DHX30)
- GSM7472854 shDHX30 #2
- GSM7472855 shDHX30 #4
- GSM7472856 shScr (DDX17)
- GSM7472857 shDDX17 #1
- GSM7472858 shDDX17 #2
- GSM7472859 shScr (DDX10)
- GSM7472860 shDDX10 #1
- GSM7472861 shDDX10 #5
- GSM7472862 shScr (DDX21)
- GSM7472863 shDDX21 #1
- GSM7472864 shDDX21 #2
- GSM7472865 shScr (DHX9)
- GSM7472866 shDHX9 #5
- GSM7472867 shDHX9 #286
- GSM7472868 Input IgG (DDX6)
- GSM7472869 Input XL1 (DDX6)
- GSM7472870 Input XL2 (DDX6)
- GSM7472871 IP IgG (DDX6)
- GSM7472872 IP XL1 (DDX6)
- GSM7472873 IP XL2 (DDX6)
- GSM7472874 Input IgG (DDX3X)
- GSM7472875 Input XL1 (DDX3X)
- GSM7472876 Input XL2 (DDX3X)
- GSM7472877 IP IgG (DDX3X)
- GSM7472878 IP XL1 (DDX3X)
- GSM7472879 IP XL2 (DDX3X)
- GSM7472880 Input IgG (DDX21)
- GSM7472881 Input XL1 (DDX21)
- GSM7472882 Input XL2 (DDX21)
- GSM7472883 IP IgG (DDX21)
- GSM7472884 IP XL1 (DDX21)
- GSM7472885 IP XL2 (DDX21)
- GSM7472886 Input IgG (DHX9)
+ 17 more — browse all 57 samples with per-sample file links →
- GSE328649 Lineage 2-Beijing Mycobacterium tuberculosis strains suppress BCG-trained innate immunity early after infection 39 samples shares suppress, immunity, innate
- GSE313850 RNA exonuclease REXO4 resolves m6A-marked R-loops and suppresses anti-tumor immunity [CUT&Tag-seq] 44 samples shares suppress, immunity
- GSE313845 RNA exonuclease REXO4 resolves m6A-marked R-loops and suppresses anti-tumor immunity [ChIP-Rx] 24 samples shares suppress, immunity
- GSE302818 SPEN is an androgen receptor dependent tumor suppressor and mediates hormonal therapy resistance in prostate cancer 38 samples shares suppress
- GSE303576 Rb-driven transcription limits its tumour suppressive effects in breast cancer 279 samples shares suppress
- GSE318420 Immunosuppressive monocytes are enriched in hepatocellular carcinoma patients with liver dysfunction in a phase II trial of combination sorafenib and nivolumab 210 samples shares suppress
- GSE299672 PHIP suppresses NuRD to enable the growth of SWI/SNF-mutant cancers [ChIP-seq] 132 samples shares suppress
- GSE294016 A macrophage-predominant, immunosuppressive immune microenvironment and subtype-specific therapeutic vulnerabilities in advanced salivary gland cancer [bulk RNA-seq] 95 samples shares suppress
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.